NTB003

Small molecule

NNanjing Chia-tai Tianqing Pharmaceutical

NTB003 is one of 30 small molecule programs targeting Thyroid Eye Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid Eye DiseaseActive, not recruiting

Thyroid Eye DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Thyroid Eye Disease

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

3 2

Zolymbus

AbbVie

Approved

1 3

Restasis

TTaiwan Bio Therapeutics Inc.

Approved

1 4

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 5

ENSPRYNG

Roche

Phase 3

2 6

Actemra

Roche

Phase 3

2 7

Cosentyx

Novartis

Phase 3

1 8

TEPEZZA

HHorizon Therapeutics Ireland DAC

Phase 3

8 9

TEPEZZA

Amgen

Approved

1 10

Linsitinib

SSling Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Not yet recruiting

Thyroid Eye Disease

NCT07462130

Clinical

Trials by Indication[1]

Tics1 trial

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

Enrolling by invitation·NNanjing Chia-tai Tianqing Pharmaceutical·Phase 1·NCT07182552·40 enrolled

Thyroid Eye Disease1 trial

An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

Not yet recruiting·NNanjing Chia-tai Tianqing Pharmaceutical·Phase 1/2·NCT07462130·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NTB003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTB003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTB003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Chia-tai Tianqing Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNanjing Chia-tai Tianqing Pharmaceutical

NTB003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Tics1 trial

Thyroid Eye Disease1 trial

References

Drug Info

Quick Facts

Related News